

## Therapeutic Focus

The Medicines Company has a singular, relentless focus on addressing the greatest global healthcare challenge and burden today – cardiovascular disease (CVD), which remains the world’s leading cause of death.<sup>1</sup> Its leading risk factor is also the most readily modifiable – cumulative exposure to elevated low-density lipoprotein cholesterol (LDL-C).<sup>2</sup>

Despite the widespread use of LDL-lowering therapies, the majority of people with atherosclerotic cardiovascular disease (ASCVD) are not achieving treatment goals.<sup>3,4</sup> Multiple factors may impact overall clinical outcomes. Many people don’t receive appropriate or sufficient treatment. Not knowing their LDL-C levels is a contributing factor. Others do not take prescribed therapies as directed. Poor adherence to therapies that require frequent administration often undermines treatment success. Even when people take their oral therapies as prescribed, not all reach their LDL-C goals.<sup>3</sup>

In 2013, The Medicines Company obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement with Alnylam Pharmaceuticals. The Company has full commercial rights to inclisiran in all markets and market exclusivity through 2034, with anticipated extensions to 2035. The Medicines Company divested its infectious disease business unit in 2018 to focus on the clinical development of inclisiran.

The Company is led by a multidisciplinary team with significant experience in pharmaceutical product development and commercialization.



### Investor Relations

Krishna Gorti, M.D.  
973.290.6122  
krishna.gorti@themedco.com



### Media Relations

Michael Blash  
973.290.6100  
michael.blash@themedco.com

### Headquarters

8 Sylvan Way  
Parsippany, NJ 07054

973.290.6000  
Toll Free: 800.388.1183

### Founded

1996

### Stock Information

NASDAQ: MDCO

### Initial Public Offering

August 8, 2000

### Employees

Approximately 65\*

### Senior Management

Mark Timney  
*Chief Executive Officer*

Richard Fires  
*Chief Human Strategy Officer*

Clive Meanwell, M.D., Ph.D.  
*Chief Innovation Officer*

Stephen Rodin  
*Executive Vice President  
and General Counsel*

Diane Sullivan  
*Chief Commercial Officer*

Chris Visioli  
*Chief Finance Officer*

Peter Wijngaard, Ph.D.  
*Chief Development Officer*

\*As of March 30, 2019

## Clinical Development


The Medicines Company is devoted to the development of inclisiran, an investigational small interfering RNA (siRNA) therapy being evaluated for its ability to lower LDL-C through twice-a-year dosing. As a siRNA, inclisiran directly targets messenger RNA and harnesses one of the body's powerful natural mechanisms, RNA interference, to prevent production of the PCSK9 protein at its source in the liver and facilitate removal of LDL-C from the bloodstream.

If approved, inclisiran would be the first cholesterol-lowering therapy in the siRNA class and is currently the only medicine in late-stage clinical development with the potential to deliver durable and potent lowering of LDL-C through twice-a-year dosing.

The efficacy and safety of inclisiran in patients with ASCVD and familial hypercholesterolemia (FH) is being studied in the ORION clinical trial program. Inclisiran is currently in Phase 3 of clinical development and is not yet approved for use by the FDA or any other regulatory authority.

## 2019 Outlook

The Company expects readouts of topline Phase 3 data to start in the second half of the third quarter of 2019 followed by anticipated regulatory filings in the U.S. in the fourth quarter of 2019 and in Europe in the first quarter of 2020.



We are excited at the prospect of bringing forward a revolutionary approach to treat cardiovascular disease using a twice-a-year therapy with unique potential to address the need for additional LDL-C lowering and long-standing medication adherence challenges faced by millions of people.

**Mark Timney**  
CEO

For More Information



[www.themedicinescompany.com](http://www.themedicinescompany.com)

Updated August 2019

<sup>1</sup> McClellan M., et al. *Circulation*. 2019;139(9):e44-e54.

<sup>2</sup> Goldstein, Cell 2015; Skalen, *Nature* 2002; Tabas, *Circ* 2007; Nordestgaard, *Eur Heart J* 2013; Cuchel, *Eur Heart J* 2014. Ference, *JACC* 2018.

<sup>3</sup> Cannon C, et al. *JAMA Cardiol*. 2017;2(9):959-966.

<sup>4</sup> Lansberg et al, *Vasc Health Risk Manag*. 2018;14:91-102.